Explore >> Select a destination
|
You are here 
|
thepsychedelicscientist.com | ||
| | | | |
www.yalemedicine.org
|
|
| | | | | Dr. Sanacora is a Professor of Psychiatry at Yale University and the Director of the Yale Depression Research Program. Dr. Sanacora's work has focused largely on elucidating the pathophysiological mechanisms associated with mood and other neuropsychiatric disorders and using this information to inform the development of novel treatment strategies. His preclinical research laboratory explores the effects of stress and pharmaceutical agents on cellular biology, neurophysiology and behavior. His clinical la... | |
| | | | |
www.nationalelfservice.net
|
|
| | | | | Kirsten Lawson focuses on novel and emerging pharmacotherapy and neuromodulation for people with 'treatment resistant depression'. | |
| | | | |
www.samwoolfe.com
|
|
| | | | | Dr Robin Carhart-Harris is a neuropsychopharmacologist (or a 'scientist' if you want to be more general) who works at Imperial College London. In the past, he worked under David Nutt, the former chairman of the Advisory Council on the Misuse of Drugs. Nutt was fired for being a bit nutty (in the eyes of the... | |
| | | | |
www.frontiersin.org
|
|
| | | Background: Anxiety disorders increase risk of future cardiovascular disease (CVD) and mortality, even after controlling for confounds including smoking, lifestyle, and socioeconomic status, and irrespective of a history of medical disorders. While impaired vagal function, indicated by reductions in heart rate variability (HRV), may be one mechanism linking anxiety disorders to CVD, prior studies have reported inconsistent findings highlighting the need for meta-analysis.Method: Studies comparing resting-state HRV recordings in patients with an anxiety disorder as a primary diagnosis and healthy controls were considered for meta-analysis.Results: Meta-analyses were based on 36 articles, including 2086 patients with an anxiety disorder and 2294 controls. Over... | ||
